These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18939385)

  • 1. Preventing renal disease progression: can complete renin-angiotensin-aldosterone blockade work?
    Schreiber MJ
    Cleve Clin J Med; 2008 Oct; 75(10):699-700, 703-4. PubMed ID: 18939385
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on proteinuric chronic kidney disease: the dual-goal approach.
    Hirsch S
    Cleve Clin J Med; 2008 Oct; 75(10):705-13. PubMed ID: 18939386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children.
    Ku E; Campese VM
    Pediatr Nephrol; 2009 Dec; 24(12):2301-7. PubMed ID: 19347366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of aldosterone receptor blocker to dual renin-angiotensin-aldosterone blockade leads to limitation of tubulointerstitial injury of kidney.
    Tylicki L; Rutkowski P; Renke M; Rutkowski B
    Kidney Int; 2007 Nov; 72(9):1164-5. PubMed ID: 17943159
    [No Abstract]   [Full Text] [Related]  

  • 6. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):542-51. PubMed ID: 19261819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?
    Wenzel U
    Kidney Int; 2007 Mar; 71(5):374-6. PubMed ID: 17315004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B
    Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperkalemia Associated with Renin-Angiotensin-Aldosterone System Inhibition in Patients with Heart Failure; Underexplored and Overrated?
    Koratala A; Aboud H; Kazory A
    Nephron; 2018; 138(3):220-221. PubMed ID: 29176327
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
    Ruiz-Hurtado G; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Salt-induced inappropriate augmentation of intrarenal RAAS and its treatment in patients with chronic kidney disease].
    Konishi Y
    Nihon Rinsho; 2012 Sep; 70(9):1588-92. PubMed ID: 23012808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of renal disease--can we forget about inhibition of the renin-angiotensin system?
    Mann JF; McClellan WM; Kunz R; Ritz E
    Nephrol Dial Transplant; 2006 Sep; 21(9):2348-51; discussion 2352-3. PubMed ID: 16822789
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.